Does nintedanib have the same effect on FVC decline in patients with progressive fibrosing ILDs treated with DMARDs or glucocorticoids?

Nazia Chaudhuri,¹ Vincent Cottin,² Stefania Cerri,³ Michael Kreuter,⁴ Maria Otaola,⁵ Diego Castillo Villegas,⁶ Craig Glazer,⁷ Heiko Müller,⁸ Carl Coeck,⁹ Toby M Maher¹⁰ on behalf of the INBUILD trial investigators

1. UMR 754, Lyon, France; ³Center for Rare Lung Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, France; ³Center for Rare Lung Diseases, Pneumology and Respiratory I seases, Pneumology and Respiratory I seases, Pneumology and Respiratory Lyon 1, UMR 754, Lyon, France; ³Center for Interstitial and Rare Lung Diseases, Pneumology and Respiratory I seases, Pneumology and Respiratory I sease 5 Evention and the end and the Rhein, Germany; ⁹SCS Boehringer Ingelheim Comm.V., Brussels, Belgium; ¹⁰National Heart and Lung Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, and Keck School of Medicine, University of Southern California, Los Angeles, California, USA

INTRODUCTION

- In the INBUILD trial in subjects with chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (other than idiopathic pulmonary fibrosis [IPF]), nintedanib slowed the rate of decline in forced vital capacity (FVC) (mL/year) over 52 weeks by 57% versus placebo.¹
- Subgroup analyses suggested that the effect of nintedanib on reducing the rate of decline in FVC was consistent across subgroups with different ILD diagnoses.²
- Autoimmune rheumatic diseases are commonly treated using disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids.


AIM

 To assess the influence of DMARDs and/or glucocorticoids at baseline on the effect of nintedanib in the INBUILD trial.

METHODS

Trial design¹

- Subjects in the INBUILD trial had an ILD other than IPF, diagnosed according to the investigator's usual clinical practice; reticular abnormality with traction bronchiectasis (with or without honeycombing) of >10% extent on HRCT; FVC \geq 45% predicted; diffusing capacity for carbon monoxide (DLco) ≥30%-<80% predicted
- Subjects met ≥ 1 of the following criteria for ILD progression in the 24 months before screening, despite management deemed appropriate in clinical practice:



- Subjects were randomised to receive nintedanib or placebo, stratified by fibrotic pattern on HRCT (usual interstitial pneumonia [UIP]-like fibrotic pattern or other fibrotic patterns).
- Patients taking stable doses of medications to treat autoimmune rheumatic diseases were eligible to participate, but patients taking azathioprine; cyclosporine; mycophenolate mofetil, tacrolimus; oral glucocorticoids >20 mg/day; the combination of oral glucocorticoids, azathioprine and N-acetylcysteine; cyclophosphamide; or rituximab were not eligible.
 - Investigators were asked not to consider patients with autoimmune disease that was managed using any of these therapies for participation in the trial. Patients who took these therapies to treat their ILD, and whose ILD was progressing, could participate in the trial if the restricted therapy was discontinued.
- Apart from the restricted therapies listed above, there was no limit on the use of stable doses of biologic or non-biologic DMARDs.
- Initiation of the above therapies was allowed after 6 months of trial treatment in subjects with deterioration of ILD or autoimmune disease.

Analyses


- We assessed the rate of decline in FVC (mL/year) over 52 weeks in subgroups by use of DMARDs and/or glucocorticoids at baseline.
- DMARDs were identified based on the WHO standardised drug grouping (SDG) plus baricitinib and excluding denosumab. Glucocorticoids (with oral, intravenous [IV], IV bolus, IV drip, or intramuscular administration) were identified based on the WHO SDG.
- Interaction p-values were calculated to assess potential heterogeneity in the treatment effect of nintedanib versus placebo across the subgroups. No adjustment for multiplicity was made.
- Adverse events are presented descriptively.









RESULTS





ILD diagnoses in subgroups by use of DMARDs and/or glucocorticoids at baseline



with an autoimmune disease noted in the "Other fibrosing ILDs" category of the case report form. †Included sarcoidosis, exposure-related ILDs and selected terms in the "Other fibrosing ILDs" category of the case report form. NSIP, non-specific interstitial pneumonia.

Rate of decline in FVC (mL/year) over 52 weeks

- In the placebo group, the rate of FVC decline was numerically greater in subjects who used DMARDs and/or glucocorticoids at baseline (Figure 1).
- Nintedanib reduced the rate of FVC decline versus placebo both in subjects who did and did not use DMARDs and/or glucocorticoids at baseline. The interaction p-value did not indicate a differential treatment effect of nintedanib between these subgroups (Figure 1).
- Similar results were observed in subgroups by use of DMARDs (only) and glucocorticoids (only) (Figures 2 and 3).






Figure 2. Rate of decline in FVC (mL/year) over 52 weeks in subgroups by use of DMARDs at baseline





Adverse events

• The adverse event profile of nintedanib was generally consistent between subgroups by use of DMARDs and/or glucocorticoids at baseline (Figures 4 and 5).





Figure 5. Proportions of subjects with adverse events leading to discontinuation of trial drug



Use of DMARDs and/or No use of DMARDs and/or glucocorticoids at baseline glucocorticoids at baseline

CONCLUSIONS

- In the INBUILD trial in subjects with progressive fibrosing ILDs, nintedanib had a consistent effect on reducing the rate of decline in FVC in subjects who did and did not use DMARDs and/or glucocorticoids at baseline.
- The adverse event profile of nintedanib was consistent between subgroups by use of DMARDs and/or glucocorticoids at baseline.

References

- 1. Flaherty KR et al. N Engl J Med 2019;381:1718-27.
- 2. Wells AU et al. Lancet Respir Med 2020;8:453-60.

Acknowledgements and Disclosures

The INBUILD trial was funded by Boehringer Ingelheim International GmbH (BI). The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors did not receive payment for the development of this poster. Editorial support and formatting assistance was provided by Elizabeth Ng and Wendy Morris of FleishmanHillard Fishburn, London, UK, which was contracted and funded by BI. BI was given the opportunity to review the poster for medical and scientific accuracy as well as intellectual property considerations.

Nazia Chaudhuri reports grants, consultancy fees and support to attend congresses from Boehringer Ingelheim and Roche. Toby M Maher reports grants and personal fees from GlaxoSmithKline and UCB; and personal fees from Apellis, Bayer, Biogen Idec, Blade, Boehringer Ingelheim, Bristol-Myers Squibb, Galapagos, Galecto, Indalo, Novartis, Respivent, Roche, Trevi.

